Filing Flows › Mirum Pharmaceuticals (MIRM) › Q3 2025
Mirum Pharmaceuticals (MIRM) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Mirum Pharmaceuticals (MIRM) reported revenue of $133M for the third quarter 2025 (Q3 2025), +47% from a year earlier and +4% from the quarter before. Operating margin was 2.0%, net earnings $2.9M (2.2% of revenue).
Mirum Pharmaceuticals, Q3 2025: revenue $133M (+47% year over year), operating margin 2.0%, net earnings $2.9M, operating cash flow $39.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $133M | +4% | +47% |
| Operating profit | $2.6M | — | — |
| Net earnings | $2.9M | — | — |
| Operating cash flow | $39.7M | +230% | +896% |
| Free cash flow | $39.5M | +231% | +938% |
What changed
Revenue was $133.0M in Q3 2025, up 47% year over year and up 4% from the previous quarter. Livmarli was the largest line at 69% of revenue. Livmarli added $33.1M year over year (up 56%), 78% of the total change.
Operating profit was $2.6M, a 2.0% margin (up 16.0 points year over year). Total costs grew 27% against revenue growth of 47%. The fastest-growing cost line was Research & development (+35%). Net earnings were $2.9M. The effective tax rate was -9.9%.
Operating cash flow was $39.7M (up 896% year over year), 1366% of net earnings. Non-cash charges added back $6.1M of depreciation and amortization and $18.1M of share-based compensation. Working capital and other items added $12.6M. Capital expenditures of $187K left free cash flow of $39.5M.
Questions
What was Mirum Pharmaceuticals' revenue in the third quarter 2025?
Mirum Pharmaceuticals (MIRM) reported revenue of $133M for the third quarter 2025 (Q3 2025), +47% from a year earlier and +4% from the quarter before.
Was Mirum Pharmaceuticals profitable in the third quarter 2025?
Operating profit was $2.6M (2.0% of revenue) and net earnings $2.9M.